Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.
British Journal of Clinical Pharmacology January 17, 2024 Hannah Thurgur, Michael T. Lynskey, Anne Katrin Schlag et al. 7 citations
Aims: To conduct a single-arm open-label feasibility trial of the safety and tolerability of a full-spectrum cannabidiol (CBD)-dominant cannabis-based medicinal product for treating the symptoms of long COVID. Methods: The treatment phase ran for a total of 21 weeks, followed by ~3 weeks without the study drug. Participants received up to 3 mL of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg...
DOI: 10.1111/bcp.15988 (opens in new tab)
Long covid treatment
Post-covid condition therapy
Chronic covid management
Long-haul covid remedy
+15